RxDoctor Payments Data

Brian Shannon

Nurse Practitioner · Marlton, NJNPI 1003214842

Payments from drug & device makers

$3,125in general payments, 2019–2025

Across 164 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$963
  • AstraZeneca$392
  • Regeneron Healthcare Solutions, Inc.$246
  • Sanofi$243
  • Philips North America LLC$180
  • Verona Pharma, Inc.$148
  • plus $953 from 17 others

What the payments were for

  • Food & beverage$2,98996%
  • Education$1364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,125 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$11,076
Medicare patients
51
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$44,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$30,941
Incruse ElliptaUmeclidinium Bromide15$7,190
Breo ElliptaFluticasone/Vilanterol11$7,007
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,903
Albuterol Sulfate HfaAlbuterol Sulfate76$1,736
Montelukast Sodium25$584
Azithromycin15$219
Fluticasone Propionate21$184
Pregabalin11$133
Prednisone25$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$963$45,13773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →